Humoral IgG1 Responses to Tumor Antigens Underpin Clinical Outcomes in Immune Checkpoint Blockade

Version
Humoral IgG1 Responses to Tumor Antigens Underpin Clinical Outcomes in Immune Checkpoint Blockade

The article 'Humoral IgG1 Responses to Tumor Antigens Underpin Clinical Outcomes in Immune Checkpoint Blockade' published in Nature Medicine focuses on the role of IgG1 responses to tumor antigens and their impact on clinical outcomes following immune checkpoint blockade.

Citation Text

This publication, 'Humoral IgG1 Responses to Tumor Antigens Underpin Clinical Outcomes in Immune Checkpoint Blockade,' examines the connection between IgG1 responses to tumor antigens and patient outcomes in immune checkpoint blockade.